EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Botanical Sources: 9

Kutki (Picrorhiza) Picrorhiza kurrooa Royle

Also called: kutki, kutaki, Picrorhiza kurroa Royle ex Benth. (orthographic variant), Picrorhiza lindleyana (illegitimate synonym), picroliv (iridoid glycoside fraction)

Kutki is a small perennial Himalayan herb whose bitter root and rhizome are used in Ayurvedic medicine. Its iridoid glycosides picroside I and II serve as quality markers. Wild populations are endangered, international trade is CITES-regulated, and human trials are few.

Category
Botanical
Part used
Root and rhizome
Strongest evidence
C Limited
Native range
Native from northeastern Pakistan to the western Himalaya (POWO: "NE. Pakistan to W. Himalaya")
Reviewed
2026-10-29

Class 3 Limited studies in people. This entry cites 1 RCT of Picrorhiza kurroa alone (source [3]: root powder versus placebo in 33 patients with acute viral hepatitis). The other human study it cites (source [4]) tested a five-herb tablet. [3]

Fact-checked 2026-10-29 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

3 topics studied2 body areas · strongest grade C

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what Kutki (Picrorhiza) does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for Kutki (Picrorhiza), evidence grade and finding
Topic studiedGradeWhat the evidence shows
Acute viral hepatitis (liver tests)CIn a small RCT (33 patients, HBsAg-negative acute viral hepatitis), root powder 375 mg three times daily for 2 weeks lowered bilirubin and liver enzymes faster than placebo (27.44 vs 75.9 days to bilirubin 2.5 mg%). [3]
Blood lipids (five-herb combination)CA pilot study in 19 patients of a tablet combining garlic, fenugreek, guggul, Picrorhiza (200 mg) and black pepper reported lower total cholesterol and triglycerides; the herb's own effect cannot be separated. [4]
Liver protection in animalsDIn rats with galactosamine-induced liver injury, 200 mg/kg orally reduced liver lipid content and liver enzymes; this is an animal model, not a human outcome. [3]

Main constituents: Kutkoside and the iridoid glycosides picroside I and II, found mainly in the rhizome and roots [1]; Picroliv: a standardized iridoid glycoside fraction of the root and rhizome [2]; Other reported classes: alkaloids, cucurbitacins, phenolics (including apocynin) and terpenes [1]

Amounts

Amounts studied and limits

Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.

  • Root powder capsules, 375 mg three times a day for 2 weeks; each capsule contained 2.72-2.88 mg picroside I and 5.50-6.00 mg picroside II (hepatitis RCT). [3]

No official upper intake level has been set.

Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Pregnancy and breastfeeding
    A 2022 review describes Picrorhiza kurroa as abortifacient and states it should be contraindicated during pregnancy.

    1 statement in the profile.

    Details and sources
  • Interactions with medicines
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Cancer evaluations (IARC, NTP)
    None found

    No IARC or NTP evaluation was found in the lists checked.

    Details and sources
  • FDA new dietary ingredient notifications
    None on FDA's list

    FDA does not approve dietary supplements. Each entry is one party's filing.

    Details and sources
  • Dose in official monographs
    None found

    No published information found in the sources checked.

    Details and sources
  • A 2022 review reports that traditional preparations have caused diarrhea, increased bowel frequency, abdominal gurgling and colic in clinical practice. [1]
  • The same review states that only a few toxicity studies have been reported and calls for further toxicological investigation. [1]
  • Pregnancy: the 2022 review describes Picrorhiza kurroa as abortifacient and states it should be contraindicated during pregnancy. [1]
Quality

Identity, quality and standardization

  • Picrorhiza scrophulariiflora is traded as a substitute; a validated HPTLC method measured picroside I at 1.258% and picroside II at 0.481% in P. kurroa, versus 1.611% and 0.613% in the substitute. [5]
  • Extracts have been standardized by HPLC for picroside I and picroside II content. [3]
Regulation

Regulatory status

  • International trade: CITES Appendix II (current listing in effect since 13 September 2007; Picrorhiza scrophulariiflora excluded), annotation #2: all parts and derivatives except seeds and pollen, and finished products packaged and ready for retail trade. [7]
  • US: FDA states that, by law, it does not approve dietary supplements or their labeling before they are marketed; firms are responsible for the safety and labeling of their products. [8]
  • US: No NDI notification naming kutki (Picrorhiza kurrooa) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [9]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • Picroside I, picroside II and kutkoside Iridoid glycosides [P1]
  • Picroliv (standardized fraction) Iridoid glycoside mixture [P2]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • No NDI notification naming kutki (Picrorhiza kurrooa) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P3]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • No IARC or NTP carcinogenicity evaluation of kutki (Picrorhiza kurrooa) was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-29). [P4]
  • NTP technical reports list checked 2026-10-29: no report on Picrorhiza found. [P5]

Liver (NIH LiverTox)

  • No published information found in the sources checked.

Interactions with medicines

  • No published information found in the sources checked.

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • No published information found in the sources checked.

Adulteration and substitution

  • Picrorhiza scrophulariiflora is described as a substitute for P. kurroa; Tiwari et al. (2012) validated an HPTLC method that quantifies picrosides in both species. [P6]

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity test of the dietary ingredient (at least one appropriate test or examination before use) — 21 CFR 111.75(a)(1)(i) requires identity verification of every component that is a dietary ingredient, unless FDA exempts the firm on petition under 111.75(a)(1)(ii). [P7]
  • Picroside I and picroside II content (HPLC or validated HPTLC) — Picrosides are the standardization markers, and the substitute P. scrophulariiflora also contains them at different levels (Tiwari et al. 2012). [P6]

Supply and conservation

  • IUCN Red List: Endangered (EN), via GBIF species API, retrieved 2026-10-29. [P8]
  • CITES Appendix II (current listing in effect since 13 September 2007; Picrorhiza scrophulariiflora excluded), annotation #2: all parts and derivatives except seeds and pollen, and finished products packaged and ready for retail trade. [P9]
  • India lists Picrorhiza kurroa among 13 medicinal plants receiving a 75% cultivation-cost subsidy; reviewers urge cultivation and conservation of these endangered species. [P10]

Absorption in people

  • No published information found in the sources checked.

Formulations studied to change absorption

Human data only.

  • No published information found in the sources checked.

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • No published information found in the sources checked.

Pregnancy and breastfeeding

  • A 2022 review describes Picrorhiza kurroa as abortifacient and states it should be contraindicated during pregnancy. [P1]

Sources for this profile

  1. Almeleebia TM, Alsayari A, Wahab S. Pharmacological and clinical efficacy of Picrorhiza kurroa and its secondary metabolites: a comprehensive review. Molecules 2022;27(23):8316 (PMID 36500409; full text PMC9738980), 2022-11-29. pmc.ncbi.nlm.nih.gov
  2. Sinha S, et al. Picroliv, the iridoid glycoside fraction of Picrorhiza kurroa, selectively augments human T cell response to mycobacterial protein antigens. Immunopharmacol Immunotoxicol 1998;20(4):579-88 (PMID 9805236), 1998-11. pubmed.ncbi.nlm.nih.gov
  3. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  4. IARC Monographs. Agents classified by the IARC Monographs (list of classifications, checked 2026-10-29), 2026-10-29. monographs.iarc.who.int
  5. National Toxicology Program. Technical Reports (list checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
  6. Tiwari SS, et al. TLC densitometric quantification of picrosides (picroside-I and picroside-II) in Picrorhiza kurroa and its substitute Picrorhiza scrophulariiflora and their antioxidant studies. Biomed Chromatogr 2012;26(1):61-8 (PMID 21413048), 2012-01. pubmed.ncbi.nlm.nih.gov
  7. eCFR. 21 CFR 111.75 (current as of October 27, 2026), 2026-10-27. ecfr.gov
  8. GBIF species API: IUCN Red List category for Picrorhiza kurrooa, 2026-10-29. api.gbif.org
  9. UNEP-WCMC / CITES Secretariat. Species+: Picrorhiza kurrooa, CITES listing (retrieved 2026-10-29), 2026-10-29. speciesplus.net
  10. Anmol, et al. Ethnopharmacologically important highly subsidized Indian medicinal plants: systematic review on their traditional uses, phytochemistry, pharmacology, quality control, conservation status and future prospective. J Ethnopharmacol 2024;320:117385 (PMID 37951375), 2024-02-10. pubmed.ncbi.nlm.nih.gov
Sources

Sources

  1. Almeleebia TM, Alsayari A, Wahab S. Pharmacological and clinical efficacy of Picrorhiza kurroa and its secondary metabolites: a comprehensive review. Molecules 2022;27(23):8316 (PMID 36500409; full text PMC9738980), 2022-11-29. pmc.ncbi.nlm.nih.gov
  2. Sinha S, et al. Picroliv, the iridoid glycoside fraction of Picrorhiza kurroa, selectively augments human T cell response to mycobacterial protein antigens. Immunopharmacol Immunotoxicol 1998;20(4):579-88 (PMID 9805236), 1998-11. pubmed.ncbi.nlm.nih.gov
  3. Vaidya AB, et al. Picrorhiza kurroa (Kutaki) Royle ex Benth as a hepatoprotective agent - experimental & clinical studies. J Postgrad Med 1996;42(4):105-8 (PMID 9715310), 1996-10. pubmed.ncbi.nlm.nih.gov
  4. Shaikh RF, et al. A comparative study on clinical evaluation of the hypolipidemic effects of Allium sativum, Trigonella foenum-graecum, Commiphora mukul, Picrorhiza kurroa, and Piper nigrum: a pilot study. Cureus 2022;14(7):e26597 (PMID 35936152), 2022-07-05. pubmed.ncbi.nlm.nih.gov
  5. Tiwari SS, et al. TLC densitometric quantification of picrosides (picroside-I and picroside-II) in Picrorhiza kurroa and its substitute Picrorhiza scrophulariiflora and their antioxidant studies. Biomed Chromatogr 2012;26(1):61-8 (PMID 21413048), 2012-01. pubmed.ncbi.nlm.nih.gov
  6. Plants of the World Online (POWO), Royal Botanic Gardens, Kew; WCVP data. Picrorhiza kurrooa Royle (accessed 2026-10-29; Kew cannot warrant the accuracy of the data), 2026-10-29. powo.science.kew.org
  7. UNEP-WCMC / CITES Secretariat. Species+: Picrorhiza kurrooa, CITES listing (retrieved 2026-10-29), 2026-10-29. speciesplus.net
  8. U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
  9. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.